All In Biotech

Drug Trial Radar · NCT04628494

A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 483 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

483

Actual

Start

Jan 13, 2021

Primary completion

Oct 13, 2025

Study completion Apr 2028

Sponsor

Lead sponsor
GenmabIndustry
Sponsor type
Industry
Collaborators
AbbVie
First posted
Nov 13, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this trial is to find out if epcoritamab, also known as EPKINLY™ and GEN3013, is safe and works well as treatment for participants with DLBCL that are not responding to treatment, have grown in size, or have come back following treatment with at least 1 prior systemic cancer therapy. All participants in this trial will be randomly assigned to receive either epcoritamab or a pre-specified investigator's choice (standard of care) chemotherapy (either rituximab + gemcitabine + oxaliplatin \[R-GemOx\], or bendamustine + rituximab \[BR\]). Participants must have failed or be ineligible to receive an autologous stem cell transplant (ASCT). Epcoritamab will be injected under the skin. Investigator's choice chemotherapy will be given intravenously. Trial details include: * The trial duration will be up to 5 years after last participant is randomized. * All trial participants have a 21-day screening period, a treatment period, and a follow-up period that continues until death. * The estimated trial duration for an individual participant depends upon the treatment arm assigned: * Participants who receive epcoritamab will have 28-day treatment cycles. Epcoritamab will be given once weekly for the first 3 months, then every other week for 6 months, then every 28 days until lymphoma progression or unacceptable adverse events. * Participants who receive investigator's choice (standard of care) chemotherapy will receive treatments either: * R-GemOx: On Day 1 (or Day 1 \& Day 2), and Day 15 (or Day 15 \& Day 16) every 28 days, for up to 4 months; or * BR: On Day 1 and Day 2 every 3 weeks for up to 4.5 months.

Conditions

  • Diffuse Large B-cell Lymphoma

Interventions

  • EpcoritamabBiological

    Following mandatory pre-medication, participants will be administered epcoritamab as a subcutaneous injection.

  • Investigator's Choice ChemotherapyDrug

    Following mandatory pre-medication, participants will be administered intravenously either BR or R-GemOx.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: Up to approximately 4 years, 9 months

Locations

186 sites in 24 countries. Site status is shown where the registry gives one.

  • Indiana Blood and Marrow Transplantation

    Indianapolis, Indiana

  • Community Health Network Cancer Center North

    Indianapolis, Indiana

  • University of Kentucky Markey Cancer Center

    Lexington, Kentucky

  • Henry Ford Health System

    Jackson, Michigan

  • MMCORC Attn Delaney Anderson

    Saint Louis Park, Minnesota

  • MD Anderson Cancer Center at Cooper

    Camden, New Jersey

  • Wake Forest Baptist Health

    Winston-Salem, North Carolina

  • The Christ Hospital Cancer Center

    Cincinnati, Ohio

  • TriHealth Cancer Institute- Good Samaritan Hospital

    Cincinnati, Ohio

  • Brooke Army Medical Center

    Fort Sam Houston, Texas

  • Community Cancer Trials of Utah

    Ogden, Utah

  • LDS Hospital

    Salt Lake City, Utah

  • Virginia Commonwealth University (VCU) Massey Cancer Center

    Richmond, Virginia

  • North Star Lodge Cancer Center

    Yakima, Washington

  • Waukesha Memorial Hospital

    Waukesha, Wisconsin

  • Flinders Medical Centre

    Bedford Park, Australia

  • Concord Repatriation General Hospital

    Concord, Australia

  • Peninsula Private Hospital Clinical Trials Unit

    Frankston, Australia

  • Icon Cancer Centre Corporate Office

    South Brisbane, Australia

  • Calvary Mater Newcastle

    Waratah, Australia

  • Westmead Hospital

    Westmead, Australia

  • Ordensklinikum Linz Barmherzige Schwestern

    Linz, Austria

  • Ordensklinikum Linz GmbH Elisabethinen

    Linz, Austria

  • Uniklinikum Salzburg, Universitätsklinik für Innere Medizin III der PMU

    Salzburg, Austria

  • ZNA Middelheim

    Antwerp, Belgium

  • AZ Sint-Jan

    Bruges, Belgium

  • Institut Jules Bordet

    Brussels, Belgium

  • Universitair Ziekenhuis Gent

    Ghent, Belgium

  • UZ Brussel

    Jette, Belgium

  • Hôpital de Jolimont

    La Louvière, Belgium

  • Universitair Ziekenhuis gasthuisberg Leuven

    Leuven, Belgium

  • AZ Nikolaas- Verenigde Ziekenhuizen van Waas en Durme

    Sint-Niklaas, Belgium

  • AZ Turnhout, Campus Sint-Elisabeth

    Turnhout, Belgium

  • CHU de Quebec-Universite Laval

    Québec, Canada

  • Aalborg Universitetshospital

    Aalborg, Denmark

  • Aarhus University Hospital, Department of Hematology, Clinical Research Unit C116

    Aarhus, Denmark

  • Clinical Research Unit, Roskilde Sygehus

    Roskilde, Denmark

  • Vejle Hospital

    Vejle, Denmark

  • HUS Cancer Center/ Clinical Trial Unit

    Helsinki, Finland

  • Oulu university hospital, Department of hematology

    Oulu, Finland

Showing 40 of 186 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.